2025欧洲肿瘤内科学会年会（ESMO Congress 2025）将于欧洲中部夏令时间10月17日-21日在德国柏林举行。目前，ESMO官网已公布研究摘要题目及作者信息。
【肿瘤资讯】特此整理了入选Presidential Symposium、Proffered Paper Session与Mini Oral Session的胸部肿瘤领域LBA研究，带您一睹前沿风采。
Presidential Symposium 2
摘要号：LBA4
Title：Phase III Study of Ivonescimab plus chemotherapy versus Tislelizumab plus chemotherapy as First-line Treatment for advanced squamous non-small cell lung cancer (HARMONi-6)
标题：依沃西单抗联合化疗对比替雷利珠单抗联合化疗作为晚期鳞状非小细胞肺癌一线治疗的 III 期研究 (HARMONi-6)
讲者：陆舜 (上海交通大学附属胸科医院)
摘要号：LBA5
Title：Sacituzumab tirumotecan (sac-TMT) vs platinum-based chemotherapy in EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC) following progression on EGFR-TKIs: results from the randomized, multi-center phase 3 OptiTROP-Lung04 study
标题：芦康沙妥珠单抗（sac-TMT）vs 铂类化疗用于 EGFR-TKI 治疗后进展的 EGFR 突变（EGFRm）非小细胞肺癌（NSCLC）：随机、多中心 3期 OptiTROP-Lung04 研究
讲者：张力 (中山大学肿瘤防治中心)
Proffered paper session: Non-metastatic NSCLC
摘要号：LBA65
Title：Neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study
标题：新辅助度伐利尤单抗（D）+化疗（CT）后，再进行手术（Sx）及辅助D或CRT及巩固D治疗可切除或边缘可切除ⅡB-ⅢB期NSCLC患者（pts）：Ⅱ期MDT-BRIDGE研究的中期分析（IA）
讲者：Martin Reck (Grosshansdorf, Germany)
摘要号：LBA69
Title：SKYSCRAPER-03: Phase 3, open-label, randomised study of atezolizumab (atezo) + tiragolumab (tira) vs durvalumab (durva) in locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) after platinum-based concurrent chemoradiation (cCRT)
标题：SKYSCRAPER-03：一项Ⅲ期、开放标签、随机研究，比较阿替利珠单抗（atezo）+ tiragolumab（tira）与度伐利尤单抗（durva）在含铂同步放化疗（cCRT）后、局部晚期、不可切除Ⅲ期非小细胞肺癌（NSCLC）中的疗效
讲者：Rafal Dziadziuszko (Gdansk, Poland)
Proffered paper session: NSCLC metastatic
摘要号：LBA72
Title：NorthStar: A Phase II Randomized Study of Osimertinib (OSI) With or Without Local Consolidative Therapy (LCT) for Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
标题：NorthStar：一项奥希替尼（OSI）联合或不联合局部巩固治疗（LCT）用于转移性EGFR突变非小细胞肺癌（NSCLC）的II期随机研究
讲者：Yasir Y. Elamin (Houston, United States of America)
摘要号：LBA75
Title：Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer (NSCLC): Results from the SOHO-01 study
标题：Sevabertinib（BAY 2927088）治疗晚期HER2突变非小细胞肺癌（NSCLC）：SOHO-01研究的结果
讲者：乐秀宁 (Houston, United States of America)
摘要号：LBA74
Title：Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC: Beamion LUNG 1
标题：宗艾替尼作为一线治疗药物用于晚期HER2突变NSCLC患者：Beamion LUNG 1
讲者：Sanjay Popat (London, United Kingdom)
摘要号：LBA77
Title：FLAURA2: exploratory overall survival (OS) analysis in patients (pts) with poorer prognostic factors treated with osimertinib (osi) ± platinum-pemetrexed chemotherapy (CTx) as first-line (1L) treatment (tx) for EGFR-mutated (EGFRm) advanced NSCLC
标题：FLAURA2：在具有不良预后因素、接受奥希替尼（osi）± 铂类-培美曲塞化疗（CTx）作为一线治疗（1L）的EGFR突变（EGFRm）晚期NSCLC患者（pts）中的探索性总生存期（OS）分析
讲者：Pasi A. Jänne (Boston, United States of America, MA)
摘要号：LBA73
Title： Final overall survival (OS) and safety analysis of the Phase 3 ALEX study of alectinib vs crizotinib in patients with previously untreated, advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
标题：阿来替尼对比克唑替尼治疗未经治晚期 ALK 阳性（ALK+）非小细胞肺癌（NSCLC）患者的 3 期 ALEX 研究最终总生存期（OS）和安全性分析
讲者：莫树锦 (中国香港中文大学医学院)
Mini Oral session 1: Non-metastatic NSCLC
摘要号：LBA100
Title：Detailed safety analysis of DeLLphi-304: the first phase 3 study to evaluate tarlatamab versus chemotherapy for previously treated small cell lung cancer
标题：DeLLphi-304研究的详细安全性分析：首个评估Tarlatamab对比化疗用于经治小细胞肺癌的III期研究
讲者：Martin H. Schuler (Essen, Germany)
摘要号：LBA101
Title：Tarlatamab as second-line (2L) treatment for small cell lung cancer (SCLC): Outcomes by chemotherapy-free interval (CFI) and prior PD-(L)1 inhibitor use in the phase 3 DeLLphi-304 trial
标题：在Ⅲ期DeLLphi-304试验中，tarlatamab作为二线（2L）治疗广泛期小细胞肺癌（SCLC）的结局，按无化疗间期（CFI）及既往PD-(L)1抑制剂使用情况分层
讲者：Pedro F. Simoes da Rocha (Barcelona, Spain)
Mini oral session 2: Non-metastatic NSCLC
摘要号：LBA66
Title：Ensartinib as adjuvant therapy in patients (pts) with stage IB–IIIB ALK-positive (ALK+) non-small cell lung cancer (NSCLC) after complete tumor resection: the phase III randomized ELEVATE trial
标题：恩沙替尼作为 IB-IIIB 期 ALK 阳性（ALK+）非小细胞肺癌（NSCLC）患者（pts）肿瘤完全切除术后辅助治疗：III 期随机 ELEVATE 试验
讲者：岳东升(天津医科大学肿瘤医院)
摘要号：LBA67
Title：Perioperative Pembrolizumab in Early-Stage Non–Small-Cell Lung Cancer (NSCLC): 5-Year Follow-Up From KEYNOTE-671
标题：帕博利珠单抗围手术期治疗早期非小细胞肺癌（NSCLC）：来自KEYNOTE-671的5年随访结果
讲者：Heather Wakelee (Stanford, United States of America, CA)
摘要号：LBA68
Title： CCTG BR.31: Adjuvant durvalumab (D) in resected non-small-cell lung cancer (NSCLC): final overall survival (OS) and minimal residual disease (MRD) analyses.
标题：CCTG BR.31：度伐利尤单抗（D）辅助治疗可切除非小细胞肺癌（NSCLC）：最终总生存期（OS）和微小残留病灶（MRD）分析
讲者：Glenwood Goss (Ottawa, Canada, Ontario)
摘要号：LBA106
Title：3D-response and multiomic correlates of Niraparib in relapsed mesothelioma: NERO, a randomised clinical trial in patients with relapsed mesothelioma
标题：尼拉帕利在复发性间皮瘤中的3D反应和多组学相关性：针对复发性间皮瘤患者的NERO随机临床试验
讲者：Dean A. Fennell (Leicester, United Kingdom)
摘要号：LBA70
Title： Association of radiomic features ± on-treatment ctDNA detection with treatment outcomes in patients with resectable NSCLC: exploratory analyses from AEGEAN
标题：可切除NSCLC患者的影像组学特征±治疗期间ctDNA检测与治疗结局的关联：AEGEAN的探索性分析
讲者：John Heymach (Houston, United States of America)
Mini oral session 2 : NSCLC metastatic
摘要号：LBA71
Title：Final Analysis of First-Line Serplulimab Plus Chemotherapy With or Without HLX04 in Advanced Nonsquamous Non-small Cell Lung Cancer: the ASTRUM-002 Phase 3 Study
标题：斯鲁利单抗联合化疗±HLX04 一线治疗晚期非鳞状非小细胞肺癌的最终分析：ASTRUM-002 3期研究
讲者：石远凯 (中国医学科学院肿瘤医院)
摘要号：LBA76
Title：Paclitaxel-bevacizumab ± atezolizumab in advanced non-squamous NSCLC progressing after chemo-immunotherapy: IFCT-2201 ADAPTABLE randomized phase II trial
标题：紫杉醇-贝伐珠单抗±阿替利珠单抗治疗化疗-免疫治疗后进展的晚期非鳞状NSCLC：IFCT-2201 ADAPTABLE随机II期试验
讲者：Arnaud Scherpereel (Lille, France)
Proffered paper session: Mesothelioma
摘要号：LBA104
Title：Primary results of DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first line treAtment in advanced pleural Mesothelioma - A phase 3 Randomised trial
标题：DREAM3R的主要结果：度伐利尤单抗（MEDI4736）联合化疗作为晚期胸膜间皮瘤一线治疗的III期随机试验
讲者：Anna K. Nowak (Perth, Australia)
摘要号：LBA105
Title：A Phase II, Open-label, Single-arm, Multi-center Study of Rivoceranib in Patients with Metastatic Thymic Epithelial Tumor, KCSG LU23-09 (THRIVE)
标题：一项评估Rivoceranib在转移性胸腺上皮肿瘤患者中的II期、开放标签、单臂、多中心研究，KCSG LU23-09 (THRIVE)
讲者：Myung-Ju Ahn (Seoul, Republic of Korea)
如有错漏之处，敬请留言补充！
ESMO Congress 2025 - Conference Calendar - ESMO Congress 2025
排版编辑：肿瘤资讯-TY
苏公网安备32059002004080号
